News
Shortcuts from other journals
FDA considers curbing use of erythropoietins for patients with cancer
BMJ 2007; 334 doi: https://doi.org/10.1136/bmj.334.7607.1297 (Published 21 June 2007) Cite this as: BMJ 2007;334:1297
The controversy surrounding overuse of synthetic erythropoietins in the US has shifted lately to patients with cancer, who are given these agents for the anaemia associated with chemotherapy⇑. While treatment helps patients avoid blood transfusions, the potential risks include thromboembolism (already seen in patients …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.